Australian Program for Drug Repurposing for Treatment Resistant Ovarian Cancer Treatment

Project Member(s): Marsh, D.

Funding or Partner Organisation: Medical Research Future Fund (MRFF - Ovarian Cancer Research)
Medical Research Future Fund (MRFF - Ovarian Cancer Research)

Start year: 2020

Publications:

Matthews, B, Wong-Brown, M, Liu, D, Yee, C, Dickson, K-A, Schneider, J, Islam, S, Head, R, Martin, JH, Ford, CE, Marsh, DJ & Bowden, NA 2024, 'Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer', Molecular Therapy: Oncology, vol. 32, no. 4, pp. 200911-200911.
View/Download from: Publisher's site

Xie, T, Dickson, K-A, Yee, C, Ma, Y, Ford, CE, Bowden, NA & Marsh, DJ 2022, 'Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival', Cancers, vol. 14, no. 19, pp. 4621-4621.
View/Download from: Publisher's site

Yee, C, Dickson, K-A, Muntasir, MN, Ma, Y & Marsh, DJ 2022, 'Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine', Frontiers in Bioengineering and Biotechnology, vol. 10.
View/Download from: Publisher's site

FOR Codes: Health, Medical And Health Sciences, Biological Sciences, Cancer therapy (excl. chemotherapy and radiation therapy), Basic pharmacology

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.